TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04522141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-control intervention
Description: Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
Study: NCT02146391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg Capsules
Study: NCT01357252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02746276

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
Study: NCT02812602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
Study: NCT04501991

Intervention type: OTHER
Intervention: antidiabetic treatment
Description: Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
Study: NCT03345420

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT03556124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - HD tDCS
Description: Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - HD tDCS
Description: Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - Conventional tDCS
Description: Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - Conventional tDCS
Description: Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
Study: NCT01926431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Study: NCT03532529

Intervention type: OTHER
Intervention: not applicable, it is an observational study
Description: not applicable, it is an observational study

Intervention type: OTHER
Intervention: not applicable, it is an observational study
Description: not applicable, it is an observational study
Study: NCT04742829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INTRAVIT ®
Description: 2 tablets per day morning and evening before meals
Study: NCT01410214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine/cisplatin
Description: In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
Study: NCT01870089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCare/PS-NIV Drägerwerk Lübeck Germany
Study: NCT02267161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric scales for infants at 3 years of age
Description: WPPSI-III, VINELAND, CBCL, NEPSY
Study: NCT04448769

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-SARS-CoV-2 IgT seropositivity
Description: Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM).
Study: NCT04247295

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Cast
Description: Application of a traditional cast

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Woodcast
Description: Application of a woodcast
Study: NCT03833414

Intervention type: PROCEDURE
Intervention: triceps lifting and olecranon osteotomy approaches
Description: two different surgical approaches for distal humerus fracture

Intervention type: PROCEDURE
Intervention: triceps lifting and olecranon osteotomy approaches
Description: two different surgical approaches for distal humerus fracture
Study: NCT04360837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment
Description: incremental and decremental positive end-expiratory pressure alveolar recruitment
Study: NCT04057846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided transgastric drainage
Description: Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS guided transgastric drainage
Description: Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
Study: NCT04387578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed orthodontic appliance and arch wires
Description: leveling and aligning stages in orthodontics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed orthodontic appliance and arch wires
Description: leveling and aligning stages in orthodontics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed orthodontic appliance and arch wires
Description: leveling and aligning stages in orthodontics
Study: NCT01775605

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Synera
Description: Synera Pain Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synera
Description: Synera Pain Patch
Study: NCT03311789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor + Gemcitabine + Cisplatin
Description: Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
Study: NCT03478033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin capsules, 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin capsules, 150mg
Study: NCT03963648

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractioned Exhaled Nitrogen Oxide measurements
Description: Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
Study: NCT00881816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel plus capecitabine
Description: All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
Study: NCT01671917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and exercise program
Description: * 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
Study: NCT04010591

Intervention type: DEVICE
Intervention: impedance measurement during urodynamic study
Description: Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
Study: NCT01628055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Privigen
Description: 10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours.
Study: NCT00470925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I MZINT injection and SPECT imaging
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
Study: NCT01459744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training for cardiologists.
Description: Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
Study: NCT04992845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Vertebral Body Tethering
Description: The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
Study: NCT04408040

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: 200-425mL convalescent plasma donated by patients previously positive for COVID-19

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: 200-425mL convalescent plasma donated by patients previously positive for COVID-19

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: 200-425mL convalescent plasma donated by patients previously positive for COVID-19

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: 200-425mL convalescent plasma donated by patients previously positive for COVID-19
Study: NCT03842241

Intervention type: DEVICE
Intervention: Non-custom made foot orthoses
Description: Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
Study: NCT02748070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flonase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonase
Study: NCT00285402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-726 Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-726 High dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-726 Placebo
Study: NCT01402882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 2 grams (1 gram over 10 minutes and 1 gram over 8 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
Study: NCT01475942

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: 4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: 4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
Study: NCT02119559

Intervention type: OTHER
Group type: OTHER
Intervention: Blood analysis by EPISPOT and CellSearch®
Study: NCT00689299

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Allergenic Extract, Cat Hair
Description: Standardized Cat Hair Allergenic Extract sublingual drops

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Allergenic Extract, Cat Hair
Description: Standardized Cat Hair Allergenic Extract sublingual drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sublingual Drops
Study: NCT01866280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Normal sleep= sleep 2300-0700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Normal sleep= sleep 2300-0700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal meals
Description: Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
Study: NCT02524847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Study: NCT01866280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal meals
Description: Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late sleep
Description: Late sleep=sleep at 0230-1030 hours
Study: NCT03561038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Franseen Needle
Description: Comparing 2 needles designed for tissue acquisition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fork-tip Needle
Description: Comparing 2 needles designed for tissue acquisition
Study: NCT03989492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systemic and local stressors
Description: Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
Study: NCT02110914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months.
Study: NCT02518802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg per day for 2 years.
Study: NCT01920308

Intervention type: DEVICE
Intervention: 5 mm Bard LifeStent Vascular Stent
Description: The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
Study: NCT03003403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program
Description: Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
Study: NCT02676934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End tidal control module in Aisys anesthesia workstation
Description: THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
Study: NCT02518802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
Study: NCT05576779

Intervention type: OTHER
Intervention: Ofatunumab
Description: All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
Study: NCT00755794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast Tablet, 10 mg, 8 weeks, daily
Study: NCT02331667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seafood
Description: The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
Study: NCT01866280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late sleep
Description: Late sleep=sleep at 0230-1030 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late meals
Description: Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late meals
Description: Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
Study: NCT03471143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)
Description: VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg